Madrigal Pharmaceuticals Director Sibold Sells 7,279 Shares at $445.63/Share.

Madrigal Pharmaceuticals, Inc. (MDGL) has announced that Director, President and CEO William John Sibold has sold 7,279 shares at a price of $445.63 per share on September 9, 2025.

Title: Madrigal Pharmaceuticals, Inc. (MDGL) CEO William John Sibold Sells Shares

Madrigal Pharmaceuticals, Inc. (MDGL), a clinical-stage biopharmaceutical company focused on developing therapies for serious liver diseases, has seen significant insider activity recently. On September 9, 2025, Director, President, and CEO William John Sibold sold 7,279 shares of the company's stock at a price of $445.63 per share. This transaction follows a series of positive developments for the company, including the European Commission’s approval of Rezdiffra for metabolic dysfunction-associated steatohepatitis (MASH) TD Cowen Sees Greater Upside in Madrigal (MDGL) Following Recent Rezdiffra Approval^[2].

The sale by Sibold is notable as it comes on the heels of the company’s strong performance and positive analyst ratings. TD Cowen analyst Ritu Baral recently raised her price target on Madrigal Pharmaceuticals to $554 from $390, maintaining a Buy rating TD Cowen Sees Greater Upside in Madrigal (MDGL) Following Recent Rezdiffra Approval^[2]. This increase reflects the regulatory approval of Rezdiffra, which is now the first and only authorized therapy in the European Union for MASH. The approval has been seen as a significant milestone for the company, with the potential to open up new revenue streams and reinforce its long-term growth profile.

Madrigal Pharmaceuticals has been the subject of increased institutional investment activity. During the first quarter, ADAR1 Capital Management LLC invested approximately $494,000 in the company, acquiring 1,490 shares ADAR1 Capital Management LLC Makes New Investment ...^[1]. Other institutional investors, such as Rhumbline Advisers and GAMMA Investing LLC, have also increased their stakes in the company. This trend suggests a growing confidence in the company's prospects.

Despite the positive developments, the stock remains highly shorted, with 98.50% of the shares owned by institutional investors and hedge funds ADAR1 Capital Management LLC Makes New Investment ...^[1]. The company's debt-to-equity ratio of 0.17 and its current ratio of 5.11 indicate a strong financial position. However, the stock's price-to-earnings ratio of -33.69 and its negative return on equity and net margin suggest that the company is still in the early stages of revenue generation.

In summary, the sale of shares by William John Sibold is a notable event for Madrigal Pharmaceuticals. The company's recent regulatory approvals and increased institutional investment activity suggest a promising outlook. However, investors should remain cautious given the stock's valuation metrics and its high short interest.

References
ADAR1 Capital Management LLC Makes New Investment ...^[1] https://www.marketbeat.com/instant-alerts/filing-adar1-capital-management-llc-invests-494000-in-madrigal-pharmaceuticals-inc-mdgl-2025-09-02/
TD Cowen Sees Greater Upside in Madrigal (MDGL) Following Recent Rezdiffra Approval^[2] https://finance.yahoo.com/news/td-cowen-sees-greater-upside-171409928.html